Anti-MUC1 CAR T-cell therapy (Guangzhou Anjie Biomedical Technology/University of Technology Sydney)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-MUC1 CAR T-cell therapy (Guangzhou Anjie Biomedical Technology/University of Technology Sydney)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionMucin-1 inhibitors
TargetsMucin-1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesGuangzhou Anjie Biomedical TechnologyThe First Affiliated Hospital Of Guangdong Pharmaceutical UniversityUniversity of Sydney
China Registration ClassN/A

Develop Information

Active CompaniesGuangzhou Anjie Biomedical TechnologyUniversity of SydneyThe First Affiliated Hospital Of Guangdong Pharmaceutical University
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A